1. Home
  2. AREB vs INDP Comparison

AREB vs INDP Comparison

Compare AREB & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AREB

American Rebel Holdings Inc.

N/A

Current Price

$0.15

Market Cap

5.5M

Sector

Industrials

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

N/A

Current Price

$1.77

Market Cap

4.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AREB
INDP
Founded
2014
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Plastic Products
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
4.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
AREB
INDP
Price
$0.15
$1.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.5M
22.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.02
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.27
52 Week High
$28.00
$13.24

Technical Indicators

Market Signals
Indicator
AREB
INDP
Relative Strength Index (RSI) 37.66 40.48
Support Level $0.12 $1.65
Resistance Level $1.34 $2.18
Average True Range (ATR) 0.02 0.18
MACD 0.02 0.00
Stochastic Oscillator 24.65 19.16

Price Performance

Historical Comparison
AREB
INDP

About AREB American Rebel Holdings Inc.

American Rebel Holdings Inc develops self-defense, safe storage, and patriotic product areas using a wholesale distribution network, utilizing personal appearances, musical venue performances, as well as e-commerce and television. It designs, manufactures, and markets concealed carry products. It offers products ranging in Backpacks, jackets, coats, and Others. The Company views its operations and manages its business as one operating segment engaged in patriotic goods, comprised of safes, soft goods, and beer.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: